Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia Enrolling
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Last Patient Last Visit Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

For more details, click here for the full news release.

Continue

Ocuphire in the News

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News
 With Vuity Approval, AbbVie Continues Stepping Into Eye Care- AbbVie Could Create Market For Other Presbyopia Players

With Vuity Approval, AbbVie Continues Stepping Into Eye Care- AbbVie Could Create Market For Other Presbyopia Players

Nov 3, 2021

Investigative Oral Retina Drug APX3330 Shows Favorable Safety, Tolerability

Oct 9, 2021

Getting the Drop on Presbyopia: A look at the pharmacologic solutions in the treatment pipeline

Sep 1, 2021

Ocuphire Recognized in Small Business Dealmakers Awards Honors

May 27, 2021

Presbyopia – A Review of Current Treatment Options and Emerging Therapies

May 24, 2021

Indiana CTSI Project Development Team support leads to phase 2 study, ZETA-1

May 17, 2021

Building Value for Pipeline Assets with Mina Sooch

Apr 14, 2021

VIDEO: Drop accelerates mydriasis reversal, reduces dim light disturbances

Apr 13, 2021

The Wall Street Analyzer

Mar 26, 2021

OIS Weekly: Company/Market Watch – Ocuphire Pharma Reports Positive Top-line Results in the MIRA-2 Phase III Registration Trial

Mar 24, 2021
RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • Next »
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use